Navigating the BPCIA Patent Dance: A Practical Guide

Document type: Guide Practice area: Intellectual Property — Patents Jurisdiction: United States (federal) Last reviewed: 5 September 2026

The patent dance runs on day counts. Twenty days, sixty days, sixty days, sixty days, fifteen days, five days, thirty days — and then a hundred and eighty. Each step has a deadline, each deadline has a consequence, and the whole sequence is conducted in private between two competitors, one of whom has just handed the other its manufacturing process.

It is unlike anything else in patent practice, and the operational discipline it requires is closer to a regulatory filing than to litigation.

This guide walks the sequence, from both sides.

PART ONE — THE APPLICANT, BEFORE FILING

Step 1: Map the estate

There is no Orange Book, so the mapping is a research project rather than a lookup.

• Search the sponsor's portfolio comprehensively: assignee searches, inventor searches, and family searches across the composition, cell line, culture, purification, formulation, device, method-of-use, and analytical method spaces.
• Include foreign counterparts and pending applications. Continuations issuing during your development program will be on the sponsor's list.
• Map expirations, including patent term extension and terminal disclaimers.
• Classify by type, because process patents are the ones that will decide the case.
• Identify which patents your process is likely to implicate, and feed that back to process development while the process can still change.

Expect a large number. For a major biologic the count can exceed one hundred, and the point of the exercise is not to clear all of them but to identify the ten or fifteen that matter.

Step 2: Compute the earliest lawful date

• Twelve years from first licensure of the reference product before approval; four years before submission. See 42 U.S.C. § 262(k)(7).
• Confirm the first licensure date, which is the reference product's original licensure — not a later supplement, indication, or presentation.
• Add pediatric exclusivity if applicable.
• Compare against the patent expirations.
• The date is the later of the exclusivity and the patents you cannot clear, which for a mature product is frequently the exclusivity.

Step 3: Design the process around the estate

This is the central technical program and the largest determinant of the litigation outcome.

• Involve patent counsel with the process development team from the first bioreactor campaign.
• For each process patent identified in Step 1, determine whether the planned process falls within the claims and, if so, whether an alternative is available.
• Document every design choice contemporaneously, with the patent-avoidance rationale stated in the development record. This becomes the non-infringement case.
• Characterize the resulting product analytically against the reference product, which the regulatory program requires anyway.
• Track claim scope changes as the sponsor's continuations issue.

The tension to manage. Process changes that avoid patents can affect comparability, and the regulatory program constrains what the process can be. Patent counsel and regulatory affairs must be in the same conversation, early.

Step 4: Decide the interchangeability path

• Model uptake as a biosimilar without interchangeability versus as an interchangeable product.
• Price the additional development required under current FDA thinking.
• Assess the first-interchangeable exclusivity available under § 262(k)(6) and whether a competitor is likely to reach it first.
• Decide whether to seek interchangeability initially or to enter first and supplement later.

Why this is a legal decision as well as a commercial one. Automatic substitution is the mechanism that produces generic-style uptake, and without it the product competes prescriber by prescriber. The revenue difference over the first two years frequently exceeds the entire patent litigation budget on both sides.

PART TWO — THE DANCE

Step 5: Decide whether to dance

The decision is made before day 20 and it shapes everything after.

In favor of dancing:

• Narrowing. The first action covers only the patents agreed or exchanged, rather than everything the sponsor wishes to assert.
• Information. The sponsor's detailed statements at steps 4 and 6 reveal its infringement and validity theories before any complaint.
• Sequencing. Patents held back come later, on a preliminary injunction posture where the sponsor carries the burden.
• Signal. Disclosing a genuinely different process tells the sponsor something about the strength of your position, and sometimes produces an early settlement.

Against dancing:

• Trade secret exposure. Your manufacturing process goes to your competitor under statutory confidentiality provisions that are narrower than a negotiated protective order.
• Time. The full sequence runs roughly nine months before the immediate action is filed.
• The process is where the patents are. Disclosing the process is disclosing the infringement analysis.

The consequence of not dancing. Under 35 U.S.C. § 271(e)(2)(C)(ii), failing to provide the application makes submission an act of infringement as to any patent that could have been listed — and 42 U.S.C. § 262(l)(9)(C) permits the sponsor to bring a declaratory judgment action on any patent claiming the product or a use of it. After Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017), that is the remedy; there is no injunction compelling disclosure.

Document the decision. A memorandum recording the analysis, prepared before day 20, is worth having.

Step 6: Day 20 — the disclosure

If dancing:

• Provide a copy of the 351(k) application.
• Provide information describing the manufacturing process.
• Prepare the process description with counsel and the technical team: disclose what the statute requires and not more. Over-disclosure cannot be recalled.
• Propose a supplemental confidentiality agreement layering ordinary protective-order machinery — designation tiers, a defined prosecution bar, sealed filing procedures, return-or-destroy obligations — on top of the statutory floor in § 262(l)(1).
• Confirm the recipients are limited as the statute requires: outside counsel who does not prosecute in the relevant space, and one in-house representative under the same restriction.
• Log the date. Every subsequent deadline runs from it.

Step 7: Days 20–80 — the sponsor's list

For the sponsor:

• The sixty-day window is short for a hundred-patent estate. Prepare the draft list before any application is filed.
• List patents that "could reasonably be asserted." Over-listing invites a fee argument later; under-listing forfeits the patent from the immediate action.
• Identify which listed patents you would be prepared to license, and on what terms. This is a strategic signal — licensing the device patents while holding the process patents narrows the fight to your strongest ground.
• Read the applicant's process description against every process patent, with the technical team.

Step 8: Days 80–140 — the applicant's response

• For each listed patent, provide a detailed statement of the factual and legal basis for non-infringement, invalidity, or unenforceability — or a statement that you will not market before expiry.
• The standard is genuinely detailed. Conclusory statements invite argument that the response was inadequate.
• Provide your own list of patents you believe the sponsor could assert, if you want them resolved now rather than later.
• Respond to the licensing offer.
• Be candid about what you concede. A patent you will not challenge should be identified as such; it narrows the case and it builds credibility for the positions you do take.

Step 9: Days 140–200 — the sponsor's reply

• For each patent the applicant contends is invalid or not infringed, provide a detailed statement of the basis for infringement and a response on validity and enforceability.
• For each patent on the applicant's list, the same.
• This document is the sponsor's litigation position, filed before the complaint. Draft it as such.

Step 10: Days 200–215 — negotiation and exchange

• Negotiate which patents will be the subject of the immediate action.
• A negotiated set is usually better for both sides than the exchange mechanism, because it lets each side pick its strongest ground rather than being constrained by the other's count.
• If no agreement: the applicant notifies the sponsor of the number of patents it will list; the parties then simultaneously exchange lists, with the applicant's number constraining the sponsor's under § 262(l)(5).
• Model the exchange arithmetic before choosing a number — the mechanism rewards careful counting.

Step 11: Day 245 — the immediate action

• The sponsor files within 30 days of the agreement or exchange.
• The action covers only the agreed or exchanged patents.
• There is no stay. FDA review proceeds in parallel and is unaffected.
• Litigate as ordinary patent litigation, with the added feature that the applicant's process is already known to the sponsor.

PART THREE — THE 180-DAY NOTICE AND THE INJUNCTION

Step 12: Give the notice early

Section 262(l)(8)(A) requires the applicant to give notice of commercial marketing 180 days before first commercial marketing.

Sandoz holds the notice may be given before licensure. Give it as early as the commercial plan permits, so the 180 days runs concurrently with the tail of FDA review rather than after it. Six months of revenue on a major product is a very large number.

What the notice does:

• Starts the 180 days.
• Triggers the sponsor's right under § 262(l)(8)(B) to seek a preliminary injunction on patents that were on either list but were not in the immediate action.

Practical mechanics: send it in writing, to the sponsor and any patent owner, documenting receipt. Log the date; the launch date depends on it.

Step 13: The preliminary injunction — for the sponsor

This replaces the automatic stay, and it must be built.

Likelihood of success. On the held-back patents. Choose them for strength rather than breadth; a motion on a weak patent damages the whole position.

Irreparable harm — the contested element, and the one that takes months to develop:

• Price erosion modeling. What happens to the reference product's net price on biosimilar entry, and why it does not recover.
• Formulary displacement. Once a payer moves to the biosimilar, the switch back is difficult and slow. Evidence from analogous products helps.
• Market share modeling, with the interchangeability status of the biosimilar as a key input.
• Loss of the ability to license. Where the sponsor has never licensed the patent, that history supports the argument that damages are an inadequate remedy.
• Why damages are not calculable — the counterfactual world in which entry did not occur cannot be reconstructed.

Balance of equities. The applicant's investment and its launch readiness cut against you. Acknowledge them.

Public interest. The hardest factor. The sponsor argues that patent enforcement supports innovation investment in a sector where development costs are enormous. The applicant argues cost savings to patients and payers. Courts weigh both, and this factor is frequently where the motion is won or lost.

Timing. File promptly after the notice. A sponsor that waits until day 150 invites a delay argument and has no time for a hearing.

Step 14: The preliminary injunction — for the applicant

Attack likelihood of success first, on the strongest non-infringement or invalidity ground. A substantial question is enough to defeat the motion.

Then attack irreparable harm:

• The sponsor's own licensing history prices the patent in dollars.
• The sponsor's damages models in other litigation show the harm is calculable.
• The sponsor delayed — it knew of the application for months and moved only after the notice.
• Market share loss is measurable, and the sponsor measures it every quarter.

Then the equities: the investment made, the manufacturing capacity committed, the supply commitments to payers and providers, and the patients waiting.

And the public interest: the price differential, the access consequences, and Congress's evident purpose in creating the pathway.

Have the bond argument ready. If an injunction issues, the bond under Rule 65(c) should reflect the applicant's lost profits during the injunction, which for a major product is a very large number and is worth litigating.

PART FOUR — CONFIDENTIALITY, LAUNCH, AND SETTLEMENT

Step 15: Manage the confidentiality exposure

The statutory floor in § 262(l)(1) limits recipients to outside counsel who do not prosecute in the relevant space and one in-house representative under the same restriction, and limits use to assessing and litigating infringement.

Layer a negotiated agreement on top:

• Designation tiers, including an outside-counsel-and-experts-only tier for the process description.
• A defined prosecution bar: scope, duration, and the technology field.
• Procedures for sealed filing and for use in depositions.
• Clawback for inadvertent production.
• Return or destruction at conclusion, with an archival exception.
• Notice obligations if the receiving party is subpoenaed.

Internal discipline on the applicant's side:

• Prepare the process description with counsel; disclose what the statute requires and no more.
• Maintain a log of what was disclosed and when.
• Brief the technical team on what the sponsor now knows.

Internal discipline on the sponsor's side:

• Segregate the received information rigorously.
• Confirm no recipient is involved in prosecution in the field.
• Do not let the information reach business or regulatory personnel.

The reason this matters. A sponsor that misuses the disclosure faces statutory and contractual consequences and, more practically, destroys its credibility with the court in a case that will turn on equitable factors.

Step 16: The at-risk launch decision

Where FDA has approved and litigation is unresolved, launching is possible and dangerous.

Model it explicitly:

The point that must be stated plainly to the board: the exposure is measured by what the sponsor loses, not by what the applicant earns. A biosimilar taking twenty percent of a $4 billion product for eighteen months creates a lost-profits claim far larger than the applicant's revenue over the same period, and for many biosimilar developers it exceeds enterprise value.

Step 17: Settle on a date

Most of these disputes settle, and the shape is familiar.

Terms:

• Entry date, before patent expiry.
• A license, frequently royalty-bearing rather than royalty-free — a difference from generic settlements.
• Acceleration triggers: another biosimilar's entry, an adverse ruling, defined events.
• Most-favored-entry provisions.
• Interchangeability treatment — whether the license covers an interchangeable presentation, and whether the entry date differs for it.
• Supply or manufacturing arrangements, where the sponsor supplies drug substance or the applicant supplies capacity.
• Dismissal terms, and treatment of any pending PTAB proceedings.

The antitrust analysis is the same as for generics. Value flowing from the sponsor to the applicant is analyzed under FTC v. Actavis, Inc., 570 U.S. 136 (2013), the settlement is reportable, and the justification analysis — litigation costs, independent value of any side arrangement — must be contemporaneous. Bring antitrust counsel into the structuring, not the review.

One BPCIA-specific term to watch. A supply agreement in which the sponsor manufactures for the applicant has obvious independent value and is common in this sector — and it is exactly the kind of side arrangement that requires a documented arm's-length pricing analysis.

PART FIVE — A WORKED SEQUENCE

Tessendorf Biologics and Harlow Biosciences, on the facts from the companion article: Velcaris, first licensed 2014, $3.4 billion in annual U.S. revenue, eleven unexpired patents.

Two years before filing. Harlow's process development team, working with patent counsel from the first campaign, redesigns its purification sequence to avoid two of Tessendorf's chromatography patents. Every trial is documented with the avoidance rationale in the development report. The change costs about $14 million in additional process development and eight months of program time.

Harlow's counsel, Adaeze Fontanelli-Brand, records the reasoning in a memorandum: the redesign is expensive, but the patents run to 2031 and the exclusivity expires in 2026, so without the redesign the entry date is five years later. The redesign pays for itself many times over.

Filing. Harlow submits its 351(k) application eighteen months before the twelve-year exclusivity expires. FDA accepts it for review.

Day 1 — the dance decision. Adaeze's memorandum sets out both paths.

Not dancing exposes Harlow to all eleven patents at once, on the sponsor's timetable, with no narrowing.

Dancing discloses the redesigned purification process — which is Harlow's principal competitive asset — to Tessendorf.

The decision: dance, on the reasoning that the process advantage is protected by the statutory confidentiality provisions and by a supplemental agreement, that the redesign is defensible and worth establishing early, and that facing three patents rather than eleven is worth a great deal.

Day 20. Harlow provides the application and process description, with a proposed supplemental confidentiality agreement. Tessendorf executes it with two modifications, both accepted.

Day 80. Tessendorf lists nine patents and offers to license the two device patents.

Day 140. Harlow's detailed statements: non-infringement of the four process patents, with the redesign explained; invalidity of both formulation patents; the device patents are moot because Harlow will market a vial presentation only; and the method-of-use patent is moot because Harlow is carving out the second indication. Harlow lists two additional patents.

Day 200. Tessendorf's reply contests non-infringement on two process patents and maintains validity of one formulation patent.

Day 215. Negotiation produces agreement on three patents — one formulation, two process. Both sides prefer this to the exchange mechanism.

Day 245. Immediate action filed in Delaware.

Month 22. Harlow gives its 180-day notice — before licensure, as Sandoz permits, running it concurrently with the last months of review. Adaeze's note: this decision alone is worth approximately $180 million in earlier revenue.

Month 23. Tessendorf moves for a preliminary injunction on the two held-back patents. Its irreparable harm showing is well developed — price erosion modeling, formulary displacement evidence from an analogous product, and testimony that it has never licensed the process patents.

Month 26. Denied on likelihood of success. Harlow's redesign, documented contemporaneously two years earlier, presents a substantial question the court cannot resolve on the motion record.

Month 26.5. Settlement: entry in six months, a royalty-bearing license at a low single-digit rate, acceleration if another biosimilar enters, and a supply agreement under which Tessendorf provides fill-finish capacity — with an arm's-length pricing analysis prepared before signing.

Month 32. Harlow launches as a biosimilar, not interchangeable. First-year revenue is roughly 40 percent below the model, because prescriber-by-prescriber conversion is slow.

Month 40. Harlow files a supplement seeking interchangeability.

The retrospective:

The process redesign was the single most valuable decision, made two years before any legal document existed, and it was possible only because patent counsel was in the room with process development.

The dance worked as designed — eleven patents to three — and the confidentiality exposure produced no identifiable harm.

The early 180-day notice was nearly free and worth six months of revenue.

The interchangeability decision cost more than the litigation. Both sides spent roughly $18 million on the patent dispute; Harlow's first-year revenue shortfall from lacking interchangeability was several times that.

PART SIX — CALENDAR, BUDGET, AND STAFFING

The day-count calendar

Two notes. The applicant controls the timing of the notice and should give it as early as commercially sensible. And the deadlines before day 245 are short for the work they require, which is why the preparation happens before day 0.

Budget

The number that dwarfs all of these is the process redesign — frequently $10 million to $50 million in development cost — and the interchangeability program, which can be comparable. The legal budget is a minority of the total investment.

Staffing

Applicant: patent counsel embedded with process development from the first campaign; regulatory counsel who understands both the 351(k) pathway and the interchangeability standard; litigation counsel experienced in preliminary injunction practice; an economist for the harm and bond arguments; and one person who owns the day counts.

Sponsor: a portfolio lawyer who can produce the list in sixty days because the draft already exists; litigation counsel; an economist working on irreparable harm from the day the application is accepted, not from the day the notice arrives; and market access counsel, because the commercial defense is often more consequential than the patent case.

Both: antitrust counsel available before any settlement conversation, and appellate counsel before any at-risk launch decision.

PART SEVEN — MISTAKES THAT RECUR

Applicant: bringing patent counsel in after the process is locked. The design-around is the case, and by the time the process is validated it cannot change.

Applicant: an undocumented design-around. Contemporaneous development records stating the avoidance rationale are the non-infringement evidence. Reconstructing them later is far weaker.

Applicant: over-disclosing the manufacturing process. Disclose what the statute requires. It cannot be recalled.

Applicant: disclosing without a supplemental confidentiality agreement. The statutory floor lacks designation tiers, clawback, sealing procedures, and a negotiated prosecution bar. Propose the agreement with the disclosure.

Applicant: giving the 180-day notice late. Sandoz permits it before licensure. Every month of delay is a month of lost revenue.

Applicant: treating interchangeability as a regulatory detail. It is the largest commercial variable in the program.

Sponsor: no draft patent list before the application is accepted. Sixty days is not enough to analyze a hundred-patent estate from scratch.

Sponsor: over-listing. Listing every patent invites a fee argument and dilutes the strong positions.

Sponsor: starting the irreparable harm work when the notice arrives. Price erosion modeling and formulary evidence take months. Start when the application is accepted.

Sponsor: moving for an injunction on a weak patent. A denial on likelihood of success frames the settlement.

Both: letting the disclosed information reach the wrong people. The statutory restrictions are narrow and the credibility cost of a breach is severe.

Both: modeling the at-risk launch by the applicant's revenue. The exposure is the sponsor's lost profits.

Both: settling without contemporaneous antitrust analysis. Supply agreements in this sector have obvious independent value and still require documented arm's-length pricing.

PART EIGHT — FREQUENTLY ASKED QUESTIONS

Do we have to dance? No. Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017) held there is no federal injunction to compel disclosure. The consequence of declining is that the sponsor may sue immediately on any patent it could have listed.

Can we give the 180-day notice before approval? Yes, and you should. That is the second holding of Sandoz.

Is there a 30-month stay? No. The sponsor's only delay mechanism is a preliminary injunction on the ordinary four-factor standard.

How many patents will be in the first action? Whatever the parties agree, or whatever the exchange mechanism produces. Narrowing from dozens to a handful is the point of the dance.

What exactly must we disclose on day 20? A copy of the 351(k) application and information describing the manufacturing process. Prepare it with counsel; the statute does not require your entire batch record.

Who at the sponsor can see it? Outside counsel who does not prosecute in the relevant field, and one in-house representative under the same restriction. See 42 U.S.C. § 262(l)(1).

How long is the exclusivity? Twelve years from first licensure of the reference product before approval; four years before submission. New indications and presentations do not restart it.

What is the difference between biosimilar and interchangeable? Interchangeability permits pharmacy substitution without prescriber intervention, subject to state law. It is the single largest driver of uptake.

What is our exposure if we launch at risk? The sponsor's lost profits, not your revenue. For a major biologic this can exceed enterprise value. Board decision, with written appellate assessment.

Will this case go to trial? Probably not. The short remaining exclusivity window, the sponsor's weak leverage without a stay, and the applicant's catastrophic exposure make a negotiated entry date the usual outcome.

PART NINE — THE PARALLEL TRACKS

The patent dance is one of four workstreams that must be coordinated, and the failures in this practice are coordination failures.

The regulatory track. FDA review proceeds on its own schedule, unaffected by the litigation. Deficiency letters, requests for additional analytical data, and inspection findings can move the approval date by months in either direction — which moves the commercially optimal notice date and the settlement leverage. Regulatory affairs must tell the litigation team when the review timeline changes, and frequently does not.

The PTAB track. A biosimilar applicant can challenge the sponsor's patents at the Board.

• In favor: a lower burden, technical judges, and a twelve-month decision. Process patents with strong printed-publication art are good candidates.
• Against: 35 U.S.C. § 315(e) estoppel; discretionary denial where the district court trial is earlier; and the Board's inability to decide non-infringement, which is usually the applicant's primary defense in this field.
• The coordination requirement: a narrow claim construction argued at the Board to avoid prior art will be quoted against the applicant on infringement. Assign one person to review every filing across both forums.

The manufacturing track. Process changes made for regulatory or yield reasons after the disclosure can change the infringement analysis. Any change to the process described in the day-20 disclosure should be routed to patent counsel before it is implemented, and — depending on materiality — disclosed.

The commercial track. Payer contracting, formulary strategy, device and presentation decisions, and site-of-care economics determine the actual revenue outcome, and each raises its own legal questions. For the sponsor, rebate structures conditioned on formulary exclusion carry antitrust exposure. For the applicant, contracting commitments made before launch constrain the at-risk analysis.

The coordination mechanism. A single weekly meeting with all four workstreams represented, one master calendar showing every deadline across all of them, and one person accountable for the interfaces. In a matter organized around day counts across four functions, somebody has to own the calendar.

PART NINE-B — WHAT HAPPENS IF YOU DO NOT DANCE

Declining to disclose is a legitimate choice, and it has a specific shape that both sides should understand before it is made.

For the applicant

What you avoid. Handing your manufacturing process to your competitor. For a developer whose process is its principal asset, this is not a small consideration.

What you accept:

• Immediate exposure to any patent the sponsor could have listed. Under 35 U.S.C. § 271(e)(2)(C)(ii), submission is an act of infringement as to any such patent, and under 42 U.S.C. § 262(l)(9)(C) the sponsor may bring a declaratory judgment action on any patent claiming the product or a use of it.
• No narrowing. The sponsor chooses the patents; there is no negotiation and no exchange.
• No preview. You do not receive the sponsor's detailed statements, so you learn its theories from the complaint rather than months earlier.
• The sponsor still gets your process — in discovery, under a protective order, on a timeline you do not control.

The practical calculation. Declining protects the process for the months between day 20 and discovery, and it protects it from the statutory recipients in favor of a negotiated protective order. Whether that is worth facing an unbounded patent list depends on how much of your defense is process-based and how many patents the sponsor realistically has.

A partial position is possible and litigated. Providing the application while resisting later steps, or providing an incomplete process description, has generated its own disputes and has consequences under § 271(e)(6). If you are going to participate, participate; if not, decline cleanly.

For the sponsor

What you gain. Freedom to select the patents, with no narrowing and no obligation to reveal your theories in advance.

What you lose:

• The applicant's process, early. You must build the infringement case from public information and from discovery, and process patents are difficult to assess without the process.
• The narrowing. Asserting fifteen patents is expensive, slow, and invites a fee argument on the weak ones.
• The information. The applicant's detailed statements would have told you where its defenses are.

The practical response. Where the applicant declines, sue on the patents you can support without the process description — formulation, device, method of use, and any composition patent still in force — and use expedited discovery to obtain the process before deciding whether to add process patents. Filing on everything at once, on incomplete information, is the error to avoid.

PART TEN — WHERE TO GET HELP

A patent lawyer who sits with process development. The single highest-return staffing decision on the applicant side. The design-around is worth more than everything the litigation team will do, and it has to happen while the process is still changeable.

Regulatory counsel who understands both the 351(k) standard and interchangeability. The comparability package, the switching study question, and the carve-out feasibility are regulatory judgments that determine the legal position.

An economist, early, on the sponsor side. Irreparable harm evidence — price erosion, formulary displacement, the irreversibility of payer switching — takes months to develop and is the element on which preliminary injunctions in this field are won and lost.

Antitrust counsel before any settlement conversation, and before any rebate or formulary contracting decision. In this sector the commercial practices draw as much scrutiny as the settlements.

Appellate counsel before an at-risk launch. The board needs an independent written probability, not the trial team's.

Market access counsel. For both sides, the payer strategy frequently determines more revenue than the patent case. A legal team that addresses only the patents has answered part of the question.

And your own manufacturing organization. They know what the process actually does, which is the fact every patent question in this practice turns on. Bring them into the room early and keep them there.

PART ELEVEN — THE ONE-PAGE VERSION

Applicant, two years out: map the estate, design the process around it with counsel present, document every choice contemporaneously, and decide the interchangeability path with a revenue model rather than a regulatory reflex.

Applicant, day 1: decide whether to dance, with the trade secret exposure quantified and the decision documented.

Applicant, day 20: disclose what the statute requires and no more, with a supplemental confidentiality agreement proposed at the same time.

Sponsor, before day 0: have the patent list drafted. Sixty days is not enough to build it from scratch.

Sponsor, from day 0: start the irreparable harm work. It is the element that decides the injunction and it takes months.

Both, days 80–215: write the detailed statements as litigation positions, because that is what they are.

Applicant, as early as commercially sensible: give the 180-day notice. Sandoz permits it before licensure and it is nearly free.

Both, at settlement: an entry date, a royalty-bearing license, acceleration triggers, and a contemporaneous antitrust justification — with counsel in the structuring, not the review.

And the framing that governs the whole exercise: there is no automatic stay. Every advantage either side has must be built, and the building starts long before the first document is exchanged.

Related documents

• Biologics and the BPCIA: The Patent Dance, Biosimilar Approval, and Exclusivity
• BPCIA Patent Exchange Checklist: A Practical Checklist
• Biosimilar Litigation Toolkit: Disclosure Lists and Preliminary Injunction Briefing
• Hatch-Waxman Litigation: The Orange Book, Paragraph IV Certifications, and the 30-Month Stay
• Running an ANDA Litigation: A Practical Guide
• Preliminary Injunctions and Temporary Restraining Orders: Emergency Relief in Federal Court
• Preliminary Injunction and TRO Application Checklist: A Practical Checklist

This guide is general information, not legal advice, and does not create an attorney-client relationship.